Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Paudyal, Bishnuhari ^a,b   Paudyal, Pramila ^b   Shah, Dilip ^a   Tominaga, Hideyuki ^b   Tsushima, Yoshito ^b   Endo, Keigo ^b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO COLLEGE OF MEDICAL SCIENCE   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; Near infrared fluorescence; Optical Imaging; VEGF

Indexed keywords

ANTIBODY; BEVACIZUMAB; CD31 ANTIBODY; SAIVI ALEXAFLUOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; FLUORESCENT DYE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; COLON CANCER; CONJUGATE; EX VIVO STUDY; FEMALE; FLUORESCENCE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFRARED RADIATION; MOUSE; NEAR INFRARED FLUOROPHORE CONJUGATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; COLON TUMOR; DIAGNOSTIC IMAGING; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; ISOLATION AND PURIFICATION; NEAR INFRARED SPECTROSCOPY; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLONIC NEOPLASMS; DIAGNOSTIC IMAGING; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MICE; SPECTROSCOPY, NEAR-INFRARED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900458770     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-21-35     Document Type: Article

References (37)

1. Molecular imaging. Weissleder R, Mahmood U, Radiology 2001 219 316 333 10.1148/radiology.219.2.r01ma19316 11323453 (Pubitemid 32336342)
2. Molecular imaging: looking at problems, seeing solutions. Herschman HR, Science 2003 302 605 608 10.1126/science.1090585 14576425 (Pubitemid 37310909)
3. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Paudyal B, Zhang K, Chen CP, Wampole ME, Mehta N, Mitchell EP, Gray BD, Mattis JA, Pak KY, Thakur ML, Wickstrom E, Nucl Med Biol 2013 40 994 999 10.1016/j.nucmedbio.2013.08.005 24074944
4. Early diagnosis of recurrent hepatocellular carcinoma with 18 F-FDG PET after radiofrequency ablation therapy. Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Iida Y, Higuchi T, Hanaoka H, Miyakubo M, Takano A, Ishikita T, Endo K, Oncol Rep 2007 18 1469 1473 17982632
5. Clinical implication of glucose transport and metabolism evaluated by 18 F-FDG PET in hepatocellular carcinoma. Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K, Int J Oncol 2008 33 1047 1054 18949368
6. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. Paudyal P, Paudyal B, Hanaoka H, Oriuchi N, Iida Y, Yoshioka H, Tominaga H, Watanabe S, Ishioka NS, Endo K, Cancer Sci 2010 101 1045 1050 10.1111/j.1349-7006.2010.01480.x 20219072
7. The multiple uses of fluorescent proteins to visualize cancer in vivo. Hoffman RM, Nat Rev Cancer 2005 5 796 806 10.1038/nrc1717 16195751 (Pubitemid 41400779)
8. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C, Cancer Res 2003 63 7870 7875 14633715 (Pubitemid 37466721)
9. Shedding light onto live molecular targets. Weissleder R, Ntziachristos V, Nat Med 2003 9 123 128 10.1038/nm0103-123 12514725 (Pubitemid 36098273)
10. Near-infrared fluorescent probes for imaging vascular pathophysiology. Klohs J, Wunder A, Licha K, Basic Res Cardiol 2008 103 144 151 10.1007/s00395-008-0702-7 18324370 (Pubitemid 351356756)
11. Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Paudyal P, Paudyal B, Iida Y, Oriuchi N, Hanaoka H, Tominaga H, Ishikita T, Yoshioka H, Higuchi T, Endo K, Oncol Rep 2009 22 115 119 19513512
12. Near-infrared optical imaging of protease activity for tumor detection. Mahmood U, Tung CH, Bogdanov A Jr, Weissleder R, Radiology 1999 213 866 870 10.1148/radiology.213.3.r99dc14866 10580968
13. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Chang SK, Rizvi I, Solban N, Hasan T, Clin Cancer Res 2008 14 4146 4153 10.1158/1078-0432.CCR-07-4536 18593993
14. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH, Neoplasia 2008 10 1028 1040 18813360
15. Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W, Am J Nucl Med Mol Imaging 2012 2 1 13 22229128
16. Targeting apoptosis for optical imaging of infection. Thakur ML, Zhang K, Paudyal B, Devakumar D, Covarrubias MY, Chen CP, Gray BD, Wickstrom E, Pak KY, Mol Imaging Biol 2012 14 163 171 10.1007/s11307-011-0490-6 21538153
17. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG, J Nucl Med 2011 52 1778 1785 10.2967/jnumed.111.092833 21990576
18. Quantum dot probes for bacteria distinguish Escherichia coli mutants and permit in vivo imaging. Leevy WM, Lambert TN, Johnson JR, Morris J, Smith BD, Chem Commun (Camb) 2008 20 2331 2333 18473060 (Pubitemid 351691997)
19. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Pierce MC, Javier DJ, Richards-Kortum R, Int J Cancer 2008 123 1979 1990 10.1002/ijc.23858 18712733
20. Optical-based molecular imaging: contrast agents and potential medical applications. Bremer C, Ntziachristos V, Weissleder R, Eur Radiol 2003 13 231 243 12598985 (Pubitemid 36798598)
21. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts. Withrow KP, Newman JR, Skipper JB, Gleysteen JP, Magnuson JS, Zinn K, Rosenthal EL, Technol Cancer Res Treat 2008 7 61 66 18198926 (Pubitemid 351238697)
22. Vascular endothelial growth factor (VEGF) and its receptors. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z, FASEB J 1999 13 9 22 9872925 (Pubitemid 29038270)
23. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF, Cancer Res 1993 53 4727 4735 8402650 (Pubitemid 23304407)
24. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K, Cancer Sci 2011 102 117 121 10.1111/j.1349-7006.2010.01763.x 21070475
25. Tumor angiogenesis: therapeutic implications. Folkman J, N Engl J Med 1971 285 1182 1186 10.1056/NEJM197111182852108 4938153
26. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Ferrara N, Hillan KJ, Gerber HP, Novotny W, Nat Rev Drug Discov 2004 3 391 400 10.1038/nrd1381 15136787 (Pubitemid 38618122)
27. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. Gasparini G, Longo R, Fanelli M, Teicher BA, J Clin Oncol 2005 23 1295 1311 10.1200/JCO.2005.10.022 15718328 (Pubitemid 46202288)
28. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, N Engl J Med 2004 350 2335 2342 10.1056/NEJMoa032691 15175435 (Pubitemid 38702844)
29. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY, Eur J Cancer 1996 32A 2474 2484 9059336
30. The biology of VEGF and its receptors. Ferrara N, Gerber HP, LeCouter J, Nat Med 2003 9 669 676 10.1038/nm0603-669 12778165 (Pubitemid 36749215)
31. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Stollman TH, Scheer MG, Leenders WP, Verrijp KC, Soede AC, Oyen WJ, Ruers TJ, Boerman OC, Int J Cancer 2008 122 2310 2314 10.1002/ijc.23404 18240146 (Pubitemid 351542336)
32. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN, J Nucl Med 2007 48 1313 1319 10.2967/jnumed.107.041301 17631557 (Pubitemid 47242797)
33. Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206. Abbas Rizvi SM, Song EY, Raja C, Beretov J, Morgenstern A, Apostolidis C, Russell PJ, Kearsley JH, Abbas K, Allen BJ, Cancer Biol Ther 2008 7 1547 1554 10.4161/cbt.7.10.6538 18708762
34. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Scheer MG, Stollman TH, Boerman OC, Verrijp K, Sweep FC, Leenders WP, Ruers TJ, Oyen WJ, Eur J Cancer 2008 44 1835 1840 10.1016/j.ejca.2008.05.026 18632262
35. Transport of molecules, particles, and cells in solid tumors. Jain RK, Annu Rev Biomed Eng 1999 1 241 263 10.1146/annurev.bioeng.1.1.241 11701489 (Pubitemid 129740012)
36. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. Fujimori K, Covell DG, Fletcher JE, Weinstein JN, J Nucl Med 1990 31 1191 1198 2362198 (Pubitemid 20213280)
37. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM, Cancer Res 2001 61 4750 4755 11406547 (Pubitemid 32691886)